Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA (NYSE: NYXH) is a pioneering health technology company focused on innovative treatments for sleep disordered breathing, particularly Obstructive Sleep Apnea (OSA). This page serves as the definitive source for official updates about their FDA-cleared Genio neurostimulation system, financial developments, and clinical research progress.
Investors and medical professionals will find curated press releases covering regulatory milestones, partnership announcements, and quarterly earnings reports. All content is sourced directly from company filings and verified channels to ensure accuracy.
Key focus areas include updates about international market expansions, clinical trial outcomes for OSA therapies, and technological enhancements to the Genio platform. Bookmark this page to stay informed about Nyxoah's progress in developing patient-centric solutions for chronic sleep conditions.
Nyxoah (Euronext Brussels & Nasdaq: NYXH) published its updated capital and voting-rights figures on November 20, 2025. Key figures: share capital €6,504,688.76; total securities carrying voting rights 43,026,460 (all ordinary shares); total voting rights (denominator) 43,026,460. The company also reported 3,258,819 rights to subscribe to voting securities not yet issued (these are granted subscription rights) and excluded 692,677 subscription rights that were issued but not yet granted.
This disclosure is provided in accordance with applicable large-shareholding disclosure rules.
Nyxoah (Nasdaq: NYXH) announced financing commitments totaling up to U.S. $77 million to accelerate U.S. commercialization of the Genio system. The package includes a €22 million private placement (5,481,678 shares at €4.00), a U.S. $5.6 million registered direct offering (1,215,964 shares at $4.6304), and a convertible bond facility of up to €45 million (first tranche €22.5 million).
Closings are expected around Nov 17–18, 2025 for equity and Dec 2025 for the first bond tranche. Net proceeds will fund U.S. commercialization, clinical research, R&D, manufacturability and general corporate purposes.
Nyxoah (NASDAQ: NYXH) reported Q3 2025 results on November 13, 2025, following FDA approval and U.S. commercial launch of the Genio system.
Key points: Q3 revenue €2.0M (+56% YoY), first U.S. commercial implants and initial U.S. revenue in September, gross margin 60.5%, cash and financial assets €22.5M on Sept 30, 2025 (down from €43.0M on June 30, 2025), and an operating loss €24.4M for the quarter. The company trained 111 surgeons and reported early reimbursement wins including Medicare and major private payers.
Nyxoah (Nasdaq: NYXH) announced it will participate in the Stifel 2025 Healthcare Conference on Tuesday, Nov. 11, 2025. The company is scheduled to present via webcast at 9:20am Eastern Time and will be available for 1x1 meetings with institutional investors attending the event.
A live webcast can be accessed on Nyxoah’s Investor Relations website and will be available for replay after the presentation.
Nyxoah (Nasdaq: NYXH) will release its third quarter 2025 financial results on November 13, 2025. Management will host a conference call and webcast the same day beginning at 22:30 CET / 16:30 ET. Investors can access the live webcast via the company’s Investor Relations page or register to join the live call and receive dial-in details and a unique access code by email. The company recommends registering at least 10 minutes before the call if planning to ask a question. An archived webcast will be available for replay shortly after the close of the call.
Nyxoah (NASDAQ: NYXH) announced on October 6, 2025 that the first U.S. commercial patients have been implanted with the Genio® system following FDA approval. The PR states the company has trained surgeons, secured Value Analysis Committee approvals, and achieved payor coverage including CMS. Dr. Andrew T. Huang performed the initial U.S. commercial implants at Townsen Memorial Health System in Houston, completing five implants in one week. Nyxoah says it will track surgeon training, VAC submissions, prior authorizations, and accounts opened as leading indicators of future revenue growth.
Nyxoah (NASDAQ: NYXH) published a transparency notification on October 3, 2025 reporting a holding change by Vestal Point Capital.
Per the notification dated September 30, 2025, Vestal Point Capital, LP now holds 1,113,575 voting rights, representing 2.97% of total voting rights (denominator: 37,544,782) as of September 24, 2025. The filing notes a downward crossing of the 3% threshold. Vestal Point Capital, LLC is the GP controlled by Ryan Wilder; Vestal Point Capital, LP acts as investment manager and may exercise voting rights at its discretion.
Nyxoah (NASDAQ: NYXH), a medical technology company focused on Obstructive Sleep Apnea (OSA) treatment, announced the expansion of its commercial presence in the Middle East. Following the first successful Genio® implant in Abu Dhabi in September 2025, the company has established new centers across Dubai, Kuwait, and Abu Dhabi.
The Genio® system, which is the only leadless, externally powered bilateral hypoglossal nerve stimulation system for treating moderate-to-severe OSA, is now available through partnerships with leading healthcare institutions in these regions. This expansion follows the company's initial Middle East launch earlier in 2025, targeting patients who cannot tolerate CPAP therapy.
["Geographic expansion into multiple Middle East markets", "Successful first Genio implant completed in Abu Dhabi", "Partnerships established with leading healthcare institutions in the region", "Entry into world-class healthcare systems with renowned Key Opinion Leaders"]Nyxoah (NASDAQ:NYXH) has filed a patent infringement lawsuit against Inspire Medical Systems in the United States District Court for the District of Delaware. The lawsuit alleges that Inspire's IV and V devices infringe on three of Nyxoah's U.S. patents (8,700,183, 9,415,215, and 9,415,216).
The Company is seeking injunctive relief and damages, while defending its proprietary Genio® system, which features bilateral stimulation, full body MRI compatibility, and an upgradable platform that eliminates the need for battery replacement surgery. CEO Olivier Taelman highlighted positive feedback from the first month of U.S. commercial launch of the Genio system for Obstructive Sleep Apnea (OSA) treatment.
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced receiving a transparency notification from Cochlear Limited and Cochlear Investments Pty Ltd following a passive threshold crossing. The notification reveals that Cochlear Investments Pty Ltd now holds 5,631,319 voting rights, representing 14.999% of total voting rights (37,544,782) as of August 29, 2025.
The change represents a passive downward crossing of the 15% threshold, with Cochlear Investments Pty Ltd's holding decreasing from 15.04% to 14.999%. Cochlear Investments Pty Ltd is a wholly owned subsidiary of Cochlear Limited, an Australian Securities Exchange-listed company with no controlling shareholder.
FAQ
What is the current stock price of NYXOAH S A (NYXH)?
What is the market cap of NYXOAH S A (NYXH)?
